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T he International Classification of Diseases, Tenth Revi-sion, defines sudden cardiac death (SCD) as death due to
any cardiac disease that occurs out of hospital, in an emer-
gency department, or in an individual reported dead on arrival
at a hospital. In addition, death must have occurred within 1
hour after the onset of symptoms. SCD may be due to
ventricular tachycardia (VT)/ventricular fibrillation (VF),
asystole, or nonarrhythmic causes (1). For the purpose of this
scientific statement on noninvasive risk stratification for
primary prevention of SCD, SCD will specifically refer to
death due to reversible ventricular tachyarrhythmias, because
this is the focus of the risk stratification techniques to be
discussed. Among patients with SCD, an overwhelming
majority have some form of structural heart disease; this
statement will be limited to risk stratification techniques for
ischemic, dilated, and hypertrophic cardiomyopathies. Al-
though other types of structural heart disease and inherited
ion channel abnormalities are also associated with a risk for
SCD, the risk stratification strategies and data in these entities
are diverse and are beyond the scope of this document.
The annual incidence of sudden arrhythmic deaths has
been estimated between 184 000 and 462 000. The American
Heart Association has promoted the concept of the “chain of
survival,” which includes early access to medical care, early
cardiopulmonary resuscitation, early defibrillation, and early
advanced care. Many of these interventions have improved
survival. Despite all of these advances, however, overall
mortality from a cardiac arrest remains high, which under-
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scores the need for risk stratification techniques to identify
patients at high risk for these events and effective interven-
tions that can prevent or abort these events. Although risk
stratification techniques have been studied for decades, their
current relevance is enhanced by the availability of medical
therapies (2) and the implantable cardioverter defibrillator
(ICD), which have been shown to reduce both total and SCD
mortality in selected high-risk patients.
In general, risk stratification techniques have been applied
to dichotomize patients into low- and high-risk groups. In
actuality, risk is a continuum. Furthermore, it has been noted
(3) that the majority of episodes of SCD actually occur in
those with low- to intermediate-risk factors and those without
known risk factors. The highest-risk subgroups, on which
much attention is focused because of the magnitude of the
risk of death, actually constitute only a small proportion of
the total number of deaths annually. Thus, a comprehensive
approach to risk stratification must account for these epide-
miological realities. Specifically, risk stratification involves a
process of identifying subjects at relatively high risk for later
major events. Although it is a widely accepted approach
within the ethos of modern medicine, it must be recognized
that there are critical weaknesses to this process. For exam-
ple, the United Kingdom Heart Disease Prevention Project (4)
addressed the question of prevention of myocardial infarction
(MI). Among all men, the absolute risk of later MI over a
5-year period is low, under 5%. If one focuses on men with
risk factors, the absolute risk increases to 7%, which corre-
sponds to a relative risk of 1.75. However, this only
accounts for 32% of all MIs that occur. If one further focuses
on a higher-risk group with risk factors plus early disease, the
absolute risk is much higher, 22%, which corresponds to a
relative risk of 5.5. Despite these higher absolute and relative
risks, however, this group only accounts for 12% of all MIs.
As Rose (5) has argued, defining risk narrowly may identify
selected individuals for whom interventions are more likely
to be beneficial but that do little for society as a whole.
Recognizing these limitations, it is worth delineating the
desirable features of a risk stratification tool for SCD. The ideal
risk stratification tool would identify most of the patients who
will experience VT or VF and exclude those who will not. In
addition, intervention (medical, surgical, or ICD) based on an
abnormal result should improve survival to a greater extent
than does intervention in similar patients with a normal result.
The potential for finding such a tool may be hampered by the
fact that many tools provide prognostic information on SCD
and non-SCD. The utility of a tool to provide risk stratifica-
tion for SCD will depend on the extent of prognostic
information regarding non-SCD. In addition, SCD, defined
by the usual criteria, is not always due to VT or VF, and its
cause can be difficult to ascertain. For practical reasons,
many studies, particularly randomized clinical trials, use an
end point of total mortality. To validate the utility of a risk
stratification tool that is specific for SCD, it is therefore
critical to have studies that address whether intervention
based on the specific risk stratification variable or tool
reduces the incidence of SCD. In this regard, ICD trials that
demonstrate an improved survival rate do represent an im-
portant confirmation that the selection process provides some
degree of risk stratification for SCD due to VT or VF,
because the ICD is a specific intervention designed to reduce
SCD. However, the demonstration that the ICD is effective
with a particular risk stratification strategy does not validate
the strategy as ideal or optimal.
The applicability of current noninvasive risk stratification
techniques will be discussed below, organized according to
the type of testing required to obtain the information, for
example, short-term ECG recordings, long-term ECG record-
ings, and exercise. A summary is provided in the Table.
Relation of Test Approaches to the
Pathophysiology of SCD
Noninvasive approaches have been developed to detect the
presence of arrhythmogenic factors that initiate and maintain
VT or VF in patients with ischemic and nonischemic heart
disease. The conditions that lead to VT/VF may occur
transiently or may develop during the course of healing from
injury to ventricular myocardium and then persist. Factors
known to trigger or modulate VT/VF include changes in
autonomic nervous system activity, metabolic disturbances,
myocardial ischemia, electrolyte abnormalities, acute volume
and/or pressure overload of the ventricles, ion channel abnor-
malities, and proarrhythmic actions of cardiac and noncardiac
drugs. Death of myocardial cells due to ischemia, toxins,
infectious agents, or chronic pressure/volume overload leads
to scar formation, alterations in chamber geometry, and
electrical and anatomic remodeling. The electrophysiological
alterations induced by these conditions initiate and maintain
VT/VF, most likely via a reentrant mechanism, although
abnormal automaticity, triggered activity, or combinations of
these mechanisms may be operative. The spectrum of nonin-
vasive methods reviewed in the sections that follow were
developed to detect the presence of factors known to serve as
substrate or triggers of VT/VF or abnormalities in ventricular
conduction and repolarization that are critical to reentry.
The specific techniques discussed are those that detect 1)
slowed conduction (QRS duration, signal-averaged electro-
cardiogram [SAECG]), 2) heterogeneities in ventricular re-
polarization (QT interval, QT dispersion, T-wave alternans),
3) imbalance in autonomic tone (heart rate variability [HRV],
heart rate turbulence, heart rate recovery after exercise,
baroreceptor sensitivity), 4) extent of myocardial damage and
scar formation (left ventricular ejection fraction [LVEF],
6-minute walk), and 5) ventricular ectopy (long-term ambu-
latory monitoring). Although many studies have explored the
value of these techniques, the precise relationship between
the presence of these abnormalities, some of which are
persistently present, and the unpredictable occurrence of
VT/VF has not been elucidated. Even abnormalities in
combinations of these techniques may fail to detect the
precise pathophysiological abnormalities that precipitate VT
or VF. The limitations of these techniques, as described in
this document, may therefore be due in part to our inadequate
understanding of the milieu responsible for initiating clinical
episodes of VT or VF. Thus, the science of risk stratification
will be enhanced by further research to elucidate the struc-
tural, electrophysiological, autonomic, genetic, and pro-
teomic milieu that precipitates SCD.
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Left Ventricular Ejection Fraction
LVEF is the most widely used measure of left ventricular
systolic function. As evaluated by radionuclide or radiograph-
ic contrast ventriculography or by 2-dimensional echocardi-
ography, LVEF offers several distinct advantages over many
other risk stratification measures in terms of accessibility by
a large number of patients and the ease of measurement and
interpretation by physicians. The accuracy of LVEF assess-
ment is approximately 2% to 6% for radionuclide angiog-
raphy (6) and in excess of 10% for both visual estimation
and calculation by Simpson’s rule with echocardiography (7).
Reduced LVEF has been the most consistently reported risk
factor for overall mortality and SCD in the heart failure
population.
The relationship between left ventricular systolic dysfunc-
tion and death due to progressive heart failure and ventricular
arrhythmias in patients who have had an MI is well estab-
lished. Studies dating back to the advent of cardiac imaging
were the first to observe the association between reduced
LVEF and outcome, with the majority of studies concluding
that LVEF 40% serves as the threshold for identifying
high-risk individuals (8 –10). The prognostic value of im-
paired left ventricular function for overall mortality and SCD
has persisted despite progress in treatments for acute MI,
including thrombolytic and -blocker therapies (11–13). An
analysis of 20 studies that enrolled 7294 postinfarction
patients found that an LVEF 30% to 40% was associated
with a relative risk of 4.3 for major arrhythmic events, with a
sensitivity and specificity of 59.1% and 77.8%, respectively
(14). Despite these observations, however, the Defibrillator in
Acute Myocardial Infarction Trial (DINAMIT) noted that
ICDs did not decrease overall mortality when implanted in
selected patients (those with low HRV or elevated heart rate)
with low LVEF within 40 days of an MI (15), a time period
of particularly increased risk for SCD (16). Similarly, the
Table. Summary of Noninvasive Risk-Stratification Techniques for Identifying Patients With Coronary Artery Disease Who Are At Risk
for Sudden Cardiac Death (SCD)
Technique Conclusion
Left ventricular ejection fraction (LVEF) Low LVEF is a well-demonstrated risk factor for SCD.
Although low LVEF has been effectively used to select high-risk patients for application of therapy to
prevent sudden arrhythmic death, LVEF has limited sensitivity: the majority of SCDs occur in patients
with more preserved LVEF.
Electrocardiogram (ECG)
QRS duration Most retrospective analyses show increased QRS duration is likely a risk factor for SCD.
Clinical utility to guide selection of therapy has not been tested.
QT interval and QT dispersion Some retrospective analyses data show that abnormalities in cardiac repolarization are risk factors for SCD.
Clinical utility to guide selection of therapy has not yet been tested.
Signal-averaged ECG (SAECG) An abnormal SAECG is likely a risk factor for SCD, based predominantly on prospective analyses.
Clinical utility to guide selection of therapy has been tested, but not yet demonstrated.
Short-term heart rate variability (HRV) Limited data link impaired short-term HRV to increased risk for SCD.
Clinical utility to guide selection of therapy has not yet been tested.
Long-term ambulatory ECG recording (Holter)
Ventricular ectopy and NSVT The presence of ventricular arrhythmias (VPBs, NSVT) on Holter monitoring is a well-demonstrated risk
factor for SCD.
In some populations, the presence of NSVT has been effectively used to select high-risk patients for
application of therapy to prevent sudden arrhythmic death. This may also have limited sensitivity.
Long-term HRV Low HRV is a risk factor for mortality, but likely is not specific for SCD.
Clinical utility to guide selection of therapy has been tested, but not demonstrated.
Heart rate turbulence Emerging data show that abnormal heart rate turbulence is a likely risk factor for SCD.
Clinical utility to guide selection of therapy has been tested, but not yet demonstrated.
Exercise test/functional status
Exercise capacity and NYHA class Increasing severity of heart failure is a likely risk factor for SCD, although it may be more predictive of risk
for progressive pump failure.
Clinical utility to guide selection of therapy has not yet been tested.
Heart rate recovery and recovery ventricular
ectopy
Limited data show that low heart rate recovery and ventricular ectopy during recovery are risk factors for
SCD.
Clinical utility to guide selection of therapy has not yet been tested.
T-wave alternans A moderate amount of prospective data suggests that abnormal T-wave alternans is a risk factor for SCD.
Clinical utility to guide selection of therapy has been evaluated, but the results to date are inconsistent.
Baroreceptor sensitivity (BRS) A moderate amount of data suggests that low BRS is a risk factor for SCD.
Clinical utility to guide selection of therapy has not yet been tested.
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Coronary Artery Bypass Graft (CABG)-Patch trial (17) also
noted no benefit of ICD therapy in a select group of patients
(those with a positive SAECG) with low LVEF undergoing
coronary artery bypass surgery. These data suggest that a low
LVEF may be as much a marker for death due to progressive
pump failure as it is for death due to SCD. Alternatively, the
dynamic nature of the healing infarction may provide a
substrate for which an ICD intervention is less likely to
provide benefit.
Remote prior MI may result in both reduced LVEF and
abnormalities of conduction and refractoriness that serve as
the substrate for ventricular tachyarrhythmias. The associa-
tion between left ventricular dysfunction due to coronary
artery disease and SCD has been examined extensively in
cohort studies and randomized, controlled trials that evalu-
ated medical therapies and ICDs. Lower LVEF has consis-
tently been demonstrated to be the strongest independent
predictor of SCD. Further supportive evidence exists in the
form of ICD trials that used LVEF either alone or in
conjunction with other risk stratification methods in the
inclusion criteria. The Multicenter Automatic Defibrillator
Trial (MADIT) demonstrated that ICDs reduced mortality by
nearly half compared with medical therapy alone in patients
with class I to III heart failure, LVEF 35% with nonsus-
tained VT (NSVT), and nonsuppressible (by procainamide)
ventricular tachyarrhythmia on electrophysiological study
(18). Subsequent analysis of the MADIT data demonstrated
that the benefit of ICD therapy was greatest in patients with
LVEF26%, especially when other risk factors were present
(19). Likewise, the Multicenter Unsustained Tachycardia
Trial (MUSTT), which enrolled patients with LVEF 40%,
noted that total mortality and arrhythmic deaths/cardiac
arrests occurred more frequently in patients with an LVEF
30% (20). MADIT-II randomized patients with prior MI
and LVEF30% to medical therapy or ICD implantation and
demonstrated a significant 31% reduction in the risk of death
with ICD implantation (21). Finally, the Sudden Cardiac
Death in Heart Failure Trial (SCD-HeFT) randomized 2521
patients with class II or III congestive heart failure and LVEF
35% due to ischemic and nonischemic cardiomyopathy and
demonstrated a significant 23% reduction in mortality in ICD
recipients compared with patients treated with medical ther-
apy (22). Because ICDs only have an impact on arrhythmic
death, the improvement in overall mortality seen in these
trials is strong evidence of the high attributable risk of death
due to arrhythmias in patients with moderate to severe left
ventricular systolic dysfunction. These trials included patients
with a range of New York Heart Association (NYHA) heart
failure classes; the independent effects of NYHA heart failure
class on risk are discussed below. Although overall risk is
higher in patients with LVEF 35% to 40%, the absolute
number of SCDs is greater in patients with more preserved
LVEF. This epidemiological paradox occurs because the
latter subgroup is much larger than the subgroup of patients
with LVEF 35% to 40%.
In patients with nonischemic dilated cardiomyopathy,
overall mortality has also been associated with LVEF (23),
although few studies addressed the relationship between
LVEF and SCD directly. Prospective observational studies
on patients with nonischemic cardiomyopathy found that
LVEF was the only significant predictor of major arrhyth-
mic events on multivariate analyses. The combination of
low LVEF (30%) and NSVT on Holter monitoring
identified the highest-risk subgroup with a relative risk
8.2-fold that of patients with LVEF 30% without NSVT
(24). The SCD-HeFT and Defibrillators in Non-Ischemic
Cardiomyopathy Treatment Evaluation (DEFINITE) trials
reported an annual rate of SCD lower than that seen
previously in cohort studies, likely as a result of high
compliance rates with appropriate medical therapies.
These studies demonstrated a trend toward reduced mor-
tality rates in patients who received ICDs (22,25).
Conclusions
There are abundant data supporting the use of LVEF to
risk-stratify patients with ischemic and nonischemic cardio-
myopathies. There are clinical scenarios, such as the imme-
diate post-MI period, in which other causes of mortality may
confound the use of LVEF as a specific predictor of SCD.
Although low LVEF identifies a group with relatively in-
creased risk, the majority of SCDs occur in patients with
more preserved LVEF, which highlights the limited sensitiv-
ity of this technique.
Electrocardiogram
QRS Duration
QRS duration is a simple measure of the duration of ventric-
ular activation measured on the 12-lead electrocardiogram
(ECG) and is a manifestation of intraventricular or interven-
tricular conduction delay or block. It is highly reproducible,
with a coefficient of variation 5% (26). In a broad sample
of patients receiving an ECG at the VA Palo Alto Health Care
System in Palo Alto, Calif, 801 (1.8%) of 44 280 had a QRS
duration 120 ms, and an additional 2300 had either right or
left bundle-branch block (27). Estimates of the prevalence of
QRS prolongation in the population with chronic congestive
heart failure range between 20% and 50% (28), consistent
with the notion that QRS prolongation becomes more prev-
alent in patients with advancing heart disease. Observational
studies suggest that QRS prolongation is a significant marker
for poor outcome in patients with depressed LVEF, especially
due to coronary artery disease (29). QRS prolongation could
be simply a surrogate marker for more advanced myocardial
disease, but it may also contribute directly to increased
mortality, because dyssynchronous ventricular activation may
cause depression of cardiac function (30). It has also been
suggested that slow conduction and the associated increase in
dispersion of ventricular recovery directly promote ventricu-
lar arrhythmias (31,32). The Coronary Artery Surgery Study
registry found that patients with bundle-branch block had
more extensive coronary artery disease, a lower mean LVEF,
and higher 2-year mortality than those with normal QRS
duration. Furthermore, the presence of left bundle-branch
block was an independent predictor of cardiovascular mor-
tality due to SCD (33). In an unselected population with
congestive heart failure, investigators found a linear associ-
ation between QRS duration and the prevalence of systolic
dysfunction, although no independent association between
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QRS duration and all-cause mortality was recognized after
adjustment for covariates (34). In contrast, the Italian Net-
work on Congestive Heart Failure also examined the role of
left bundle-branch block and found a higher prevalence of
advanced heart failure and a 35% increased risk of SCD at 1
year (35). Similarly, a retrospective analysis of 669 patients
with congestive heart failure of varying causes found that
QRS duration120 ms was independently associated with an
increase in all-cause mortality and SCD, especially in patients
with LVEF 30% (36).
Subgroup analyses of randomized, controlled ICD trials in
patients at increased risk for SCD have also examined the role
of QRS prolongation as a predictor of overall mortality and
arrhythmic death. MADIT-II found no significant differences
in the effect of ICD therapy on overall mortality or mortality
due to SCD in subgroup analyses stratified according to QRS
duration or the presence or absence of left bundle-branch
block (37). Independent analysis of the MADIT-II data by the
Centers for Medicare and Medicaid Services concluded that a
QRS duration120 ms was, in fact, an important indicator of
which patients were likely to benefit from ICD therapy (38).
Similarly, subgroup analysis from MUSTT concluded that
patients with intraventricular conduction delay or left bundle-
branch block (but not right bundle-branch block) had a 50%
increase in the risk of cardiac arrest and total mortality,
independent of LVEF and results of electrophysiological
testing (39). Data presented from SCD-HeFT showed that the
magnitude of ICD benefit depended on the definition of the
cutoff point. For those patients with QRS duration 120 ms,
the hazard ratio was 0.67 (95% confidence interval [CI] 0.49
to 0.93) versus a hazard ratio of 0.84 (95% CI 0.62 to 1.14)
for those with QRS duration 120 ms. In contrast, when the
QRS duration cutoff was 120 ms, the hazard ratio was 0.80
(95% CI 0.57 to 1.13) versus a hazard ratio of 0.74 (95% CI
0.46 to 0.99) for those with QRS duration 120 ms. Finally,
in patients with ICDs, QRS duration has not been found to be
a predictor of VT/VF that requires ICD therapy (40,41).
These varied findings may reflect significant differences in
the design and inclusion criteria between studies. In addition,
because of the inherent limitations of subgroup analyses, any
conclusions must be interpreted with caution.
The majority of cohort studies performed on patients with
nonischemic dilated cardiomyopathy have not demonstrated a
significant association between intraventricular conduction
delay and SCD (24,42,43). ICD trials that included patients
with nonischemic cardiomyopathy also evaluated the inde-
pendent prognostic value of QRS width. DEFINITE did not
show a relationship between QRS duration and all-cause
mortality (25). SCD-HeFT, which enrolled patients with
ischemic and nonischemic cardiomyopathies, reported that
ICD therapy yielded a greater mortality reduction in patients
with QRS duration 120 ms, but specific information on the
relationship between QRS duration and mortality reduction in
patients with nonischemic cardiomyopathy has not been
presented (22).
Conclusions
A moderate amount of data show that increased QRS duration
identifies patients at higher risk for SCD, although the data
are not uniform. In the absence of prospective trials specifi-
cally designed to address this issue, the use of QRS duration
to further risk-stratify patients with congestive heart failure
for SCD is not recommended at this time.
QT Interval and QT Dispersion
The QT interval is a reflection of the summed ventricular
action potential durations. It shortens with increasing heart
rate and is commonly corrected (QTc) by Bazett’s formula
(QT interval divided by the square root of the R-R interval),
although limitations of this correction are widely recognized.
The normal corrected QT interval is slightly shorter in men
than in women. The measured QT interval is influenced by
the leads available for analysis and QRS prolongation, which
makes assessment of the relative significance of QT prolon-
gation alone problematic in many studies. QT-interval mea-
surements have been shown to be highly reproducible (44),
but the need for rate correction with suboptimal formulas
limits the comparability of QT data in populations. QT
prolongation has been associated with mortality in some
observational studies in patients with depressed left ventric-
ular function (45) but not in others (46,47). Although a
relation of QT interval to overall cardiovascular risk is
demonstrable in large populations (48,49), studies evaluating
the QT interval for prediction of SCD risk in individuals who
do not have long-QT syndrome have demonstrated mixed
results but generally link prolonged QT intervals with in-
creased risk (50). Interobserver and intraobserver variability
reduce the reproducibility for QT-interval measurement, as
well as QT dispersion.
QT dispersion (the maximal difference between QT inter-
vals in the surface ECG) was postulated to reflect dispersion
of myocardial recovery and to be associated with arrhythmia
risk. It has been associated with increased mortality in some
observational studies (45,51,52). Several recent studies have
found no relation between QT dispersion and outcome
(24,46,53–55). Lack of a clear physiological correlate further
clouds the utility of this parameter.
Dynamic changes in QT interval during a recording period
have been suggested as a marker of repolarization instability
that might be linked to arrhythmia susceptibility (56 – 60).
The QT/R-R–interval relationship for an individual patient is
highly stable over time (61). A steep slope of the relation
between QT interval and preceding R-R interval has been
associated with SCD and mortality in initial observational
studies (56,57). In a substudy of 476 patients who received
ICDs for primary prevention of SCD in MADIT-II, increased
QT variability was associated with an increase in spontaneous
VT or VF, but 22% of patients in the lowest quartile for QT
variability also experienced arrhythmias, which suggests a
poor negative predictive value (59).
Conclusions
Some data exist that link abnormalities in cardiac repolariza-
tion with an increased risk for SCD. The present data do not
support the use of QT interval, QT dispersion, or QT-interval
variability for risk stratification for SCD in patients without
the long-QT syndrome. Further studies are needed to estab-
lish whether there is clinical utility of these parameters for
risk stratification.
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Signal-Averaged ECG
In patients with VT, delayed or prolonged activation of small
portions of the ventricle are common in regions of infarction
or scar. Most infarctions do not result in complete transmural
necrosis. The amount of surviving myocardium varies, as
does its location. The increased separation of myocardial
bundles and the disruption of their parallel orientation by
fibrosis slows ventricular activation (62). During sinus
rhythm, delayed ventricular activation, often extending be-
yond the end of the QRS complex, is more profound and is
detectable at more cardiac sites in patients with sustained VT
rather than in those without VT (63). Late potentials refer to
low-amplitude signals that occur after the end of the QRS
complex. Late potentials have been recorded in dogs with
experimental infarction and correspond in time with frag-
mented and delayed electrograms recorded from the epicar-
dium (64). In patients, late potentials have been correlated
with late fragmented electrograms recorded directly from the
heart and are related to the total mass of slowly activated
tissue (63). Late potentials have been thought to represent a
substrate for reentry and have been correlated in some studies
(65), but not in others (66), with the site of earliest activation
during VT.
Signal averaging to reduce noise allows high gain ampli-
fication and filtering to expose these signals on the surface
ECG. Three time-domain measures of late potentials are
commonly assessed for evidence of late potentials: QRS
duration, low-amplitude signal duration, and root mean
square voltage of the terminal 40 ms of the QRS. Delayed
activation of the ventricle by bundle-branch block can ob-
scure detection of late potentials, and these patients have been
excluded from some analyses (67–71). Prolonged filtered
QRS duration (114 to 120 ms) appears to be the most robust
measure correlated with outcome (70,72–74). Low-amplitude
signal duration and root mean square measures were not
associated with arrhythmic events in a large post-MI study
(70). The SAECG is moderately reproducible (75), although
its reproducibility is impaired by the presence of late poten-
tials and low residual noise (76). The SAECG is either not
useful or less useful in patients with right and left bundle-
branch blocks.
Low-amplitude signals from regions of scar may also be
obscured if the abnormal region is depolarized during the
QRS. Analysis of transmural ventricular activation during
sustained VTs from patients with healed infarction has
confirmed that reentrant circuits involve intramural pathways
located at the infarct border zone, with delayed conduction in
the midmyocardium or subendocardium constituting a critical
part of the circuit (77). Analysis of sinus beats from these
patients demonstrated that activation of the myocardium that
composed the reentrant circuit began shortly after the onset of
the QRS complex and contributed little to the terminal QRS
complex or ST segment. Instead, late potentials detected in
SAECGs from these patients correlated with the region of
myocardium activated last, which was both spatially and
temporally remote from that responsible for VT in some
patients (78). Frequency analysis and analysis of spectral
turbulence of the SAECG may expose the presence of
abnormal activity that is not dependent on the timing of
depolarization of abnormal regions, but these analyses are
more involved and may be less reproducible (79 – 85).
The SAECG has been evaluated early after acute MI
(12,71,79,86 –91). Because the SAECG appears to be linked
to the substrate of the underlying infarction, it would be
expected that therapies that alter the substrate or its develop-
ment will alter the SAECG and perhaps the risk of SCD.
Thus, thrombolytic therapy reduces the incidence of an
abnormal SAECG in MI survivors (91–94). SAECG per-
formed early after MI is abnormal in 15% to 35% of patients.
SCD or cardiac arrest occurs in 3.3% to 9% of these patients
over the following 1 to 3 years (12,14,70,71,79). For the
prediction of SCD or arrhythmic events, the sensitivity of an
abnormal SAECG has been reported to vary from 30% to
76% and the specificity from 63% to 96%. The relatively low
rate of events, however, results in a low positive predictive
value for SCD, ranging from 7% to 40% (7% and 17%,
respectively, in the 2 largest studies [14]). The negative
predictive value is high, exceeding 95%, but this is also
related to the low event rate.
Prolonged QRS duration on SAECG is associated with
increased mortality and increased risk of arrhythmic events
(95–97). The MUSTT investigators assessed the relation of
the SAECG to arrhythmic events in 1268 patients with LVEF
40% and NSVT who did not have bundle-branch block
(96). Recent acute MI had occurred in 15% of the subjects. A
prolonged filtered QRS 114 ms was associated with a 28%
risk of arrhythmic events during 5 years of follow-up com-
pared with a 17% risk of events for those with shorter filtered
QRS durations (hazard ratio 1.90, 95% CI 1.46 to 2.46).
Prolonged QRS duration was also associated with inducible
sustained monomorphic VT or polymorphic VT induced by 2
extrastimuli, with a sensitivity of 46%, specificity of 57%,
positive predictive value of 42%, and negative predictive
value of 62%.
The strategy of placing an ICD in patients with a positive
SAECG was tested in the CABG-Patch study, which enrolled
patients with LVEF 36% who had an abnormal SAECG
and were undergoing coronary artery bypass surgery. At the
time of surgery, patients were randomized to receive or not
receive an ICD. ICD therapy did not improve survival,
although arrhythmic deaths were reduced (17,98). Revascu-
larization may have reduced the risk of SCD, or the criteria of
a low LVEF and a positive SAECG may not have resulted in
the selection of a group that was at sufficiently high risk when
bypass surgery was being performed. In a series of 561
patients undergoing coronary artery bypass surgery, 72% of
whom had preserved ventricular function, the postoperative
SAECG was abnormal in 27% of patients, but this was not
related to outcome (99).
In patients with nonischemic dilated cardiomyopathy, ev-
idence of late potentials detected by SAECG has been
associated with a history of ventricular arrhythmias (100 –
102). SAECG has predicted SCD and total mortality in some
studies (103) but not in others, including 3 relatively large
series of 137, 202, and 343 patients, respectively (24,104 –
109). Some studies have found that an abnormal SAECG
predicted death due to progressive heart failure rather than
SCD (110,111).
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Conclusions
Abundant data show that an abnormal SAECG may identify
patients with prior MI at risk for SCD. Given the high
negative predictive value of this test, it may be useful for the
identification of patients at low risk. Routine use of the
SAECG to identify patients at high risk for SCD is not
adequately supported at this time. Further studies are required
to assess the utility of this test.
Short-Term HRV
Analysis of HRV provides a means of assessing autonomic
nervous system modulation of the sinus node to infer auto-
nomic activity on the rest of the heart, particularly the
ventricles. Although the contributions of sympathetic and
parasympathetic tone may be difficult to dissect in individual
circumstances, studies using autonomic blockade have dem-
onstrated that HRV is almost completely due to autonomic
input to the sinus node. HRV then provides a surrogate for the
autonomic effects in the ventricle that are postulated to be
important in the pathogenesis of VT and VF. Cardiac arrhyth-
mias are often initiated by or occur in patients with enhanced
sympathetic and diminished parasympathetic tone. Thus, it
has been proposed that an analysis of HRV, particularly its
parasympathetic effects on the sinus node, can potentially
predict mortality. Spectral analysis of heart rate identifies
periodic oscillations in rate that are high-frequency (0.15 to
0.45 Hz) and low-frequency (0.04 to 0.15 Hz) ranges (112).
Respiratory sinus arrhythmia mediated by fluctuations in
parasympathetic tone is a major determinant of the high-
frequency component. Sympathetic nervous activity contrib-
utes importantly to low-frequency HRV. Other factors are
also involved, and the genesis of HRV in health and disease
is not completely understood. The relative roles of heart rate
and HRV as indicators of autonomic activity and prognosis
continue to be debated (113,114). Although short-term HRV
has moderate reproducibility in normal subjects, it is less
reproducible in patients with congestive heart failure (115).
Furthermore, there is marked interindividual variation in the
relationship of short-term HRV to parasympathetic effect
(116). Thus, the identification of clear limits for the differ-
entiation of normal and abnormal results in an individual may
be difficult.
In a 900-subject cohort of adults, those in the lowest tertile
for HRV assessed from 2-minute ECG recordings had an
increased risk of cardiovascular death (117). A small study of
patients evaluated early after MI did not find a relation of
short-term HRV to arrhythmic events, possibly owing to
sample size (118). In patients with chronic heart failure, La
Rovere and coworkers (119) analyzed 8-minute recordings
during quiet rest with spontaneous breathing or controlled
breathing. A diminished ratio of low- to high-frequency
power during spontaneous breathing, a standard deviation of
R-R intervals 15 ms, and diminished low-frequency power
during controlled breathing were univariate predictors of
arrhythmic mortality. In multivariate analysis, diminished
low-frequency power during controlled breathing was asso-
ciated with a 5-fold increase in arrhythmic mortality. The
combination of preserved low-frequency power and fewer
than 86 ventricular premature beats (VPBs) per hour was
associated with a 3% SCD risk compared with 23% for the
remainder of the population.
Conclusions
Limited data link impaired short-term HRV to sudden death.
At the present time, its use for risk stratification for SCD is
not recommended.
Long-Term Ambulatory ECG
Recording (Holter)
The ambulatory ECG (AECG) or Holter monitor has been
available for decades, and the clinical utility of the device has
expanded and changed over the years. This section addresses
quantification of ventricular arrhythmias (VPBs and NSVT)
and HRV/heart rate turbulence recorded by the AECG as a
tool for assessing risk for SCD. This is drawn in part from the
American College of Cardiology/American Heart Associa-
tion guidelines for ambulatory electrocardiography (120).
Ventricular Ectopy and NSVT
Although the AECG can reliably record the presence of VPBs
and NSVT, the day-to-day reproducibility of the frequency of
these arrhythmias is poor (120). In the 1970s and 1980s,
observational studies demonstrated that VPBs (generally 10
or more VPBs per hour) and NSVT as recorded by an AECG
in post-MI patients were risk factors for subsequent mortality
(8,10,121,122). Data suggest that ectopy beyond 10 VPBs per
hour does not convey a further increase in risk (123). It has
also been suggested that VPBs are an independent predictor
of mortality, whereas NSVT may not be a predictor (124).
The initial studies described patients without reperfusion, but
a similar relationship has been observed (although with
somewhat reduced risk) in the era of thrombolysis and acute
reperfusion (13,123,125–127). In the Gruppo Italiano per lo
Studio della Sporavvivenza nell’ Infarto Miocardico 2
(GISSI-2) study (127), mortality was 5.5% at 6 months for
patients with 10 VPBs per hour compared with 2% in those
with less frequent ectopy. The positive predictive value of
ventricular ectopy after MI for predicting cardiac arrhythmic
events or death generally ranges from 5% to 15%, with a
negative predictive value of 90% or more (120). When
combined with reduction of LVEF, ventricular ectopy be-
comes a stronger risk factor for mortality. In the European
Myocardial Infarction Amiodarone Trial (EMIAT), among
postinfarction patients with LVEF 40%, mortality was
higher in patients with frequent or complex arrhythmias on
AECG than in those without (20% versus 10%) (128).
Patients with nonischemic cardiomyopathy are at increased
risk of SCD and frequently have high-grade ventricular
ectopy and NSVT (129,130); however, the relationship be-
tween arrhythmias on AECG and cardiac arrest is much less
clear than in the case of ischemic cardiomyopathy (120).
Observational trials make up the majority of data available,
and NSVT is used more commonly than ventricular ectopy
for risk stratification, likely in relation to the high frequency
of VPBs in this population. The Gruppo de Estudio de la
Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)
trial, which included a majority of patients with nonischemic
cardiomyopathy, confirmed the prevalence of ventricular
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arrhythmias on AECG in patients with heart failure and
LVEF 35% (131). NSVT was an independent predictor of
mortality, but ventricular couplets appeared to be equally
predictive (132). Couplets and/or NSVT were detected in
62.7% of the study population, with a 50.8% mortality rate.
The remaining 37.3%, without couplets or NSVT, had a
lower mortality rate of 26.3%.
The sensitivity of NSVT in relationship to SCD or total
death varies among several studies, ranging from 31% to 71%
(120,122,129,130,133–135). The positive predictive value is
low, ranging from 20% to 50%, although the negative
predictive value has been cited as 72% to 93%.
There is a long history of intervention trials designed to
reduce mortality in high-risk patients with VPBs or NSVT.
The Cardiac Arrhythmia Suppression Trial (CAST) was a
groundbreaking, double-blind, randomized study that demon-
strated that suppression of ectopy and nonsustained VT after
MI with type IC antiarrhythmic drug therapy actually in-
creased mortality in this population (136). CAST demon-
strated that markers of risk are not necessarily appropriate
targets for therapeutic interventions. Randomized, controlled
trials have used NSVT, often documented by AECG, to
identify patients who should undergo electrophysiological
testing and further treatment if VT was inducible (18,137).
These studies showed significant 50% to 60% reductions in
mortality in the ICD-treated groups, but intervention was
based on electrophysiological testing.
In patients with nonischemic cardiomyopathy and conges-
tive heart failure, LVEF 35%, and ventricular arrhythmias
(NSVT or an average of 10 or more VPBs per hour),
DEFINITE demonstrated a trend toward improvement in
overall survival (hazard ratio 0.65, 95% CI 0.40 to 1.06,
P0.08) and a reduction in arrhythmic events (hazard ratio
0.20, 95% CI 0.06 to 0.71, P0.006) with ICD therapy. The
mortality rate of the non-ICD group was 7% per year, but no
comparison group of patients without ventricular arrhythmias
was reported.
Conclusions
There is abundant information linking the detection of ven-
tricular arrhythmias (VPBs, NSVT) on AECG in post-MI
patients with left ventricular dysfunction for risk assessment
for sudden death. Use of the AECG in this setting has been
classified as a class IIb recommendation (120); however, the
incremental risk stratification provided by this finding in
patients with LVEF 35% is unclear (22). On the other hand,
patients with LVEF between 35% and 40% (137) may
warrant AECG recording to assess for NSVT, because this
group has been shown to benefit from an ICD if VT is
induced at electrophysiological study. Patients with preserved
left ventricular function after MI are generally at low risk, and
current data suggest that they would not benefit from under-
going risk stratification with AECG recording. Finally, in
patients with dilated cardiomyopathy, DEFINITE (25) re-
quired the presence of ventricular ectopy or NSVT on AECG,
whereas SCD-HeFT (22) did not; thus, the utility of AECG
for risk stratification in this population remains unclear.
Long-Term HRV
Three groups of techniques have been used to quantitatively
examine HRV from long-term AECG recordings and address
its ability to supply prognostic information in patients with
underlying cardiac disease; these have been summarized in a
joint European Society of Cardiology/North American Soci-
ety for Pacing and Electrophysiology report published in
1996 (112). The time- and frequency-domain indices have
been evaluated extensively. Power spectral analysis has
focused on several different frequency bands (138): ultralow
frequency, very low frequency, low frequency, and high
frequency, with power expressed in absolute or normalized
units. There remains debate about which factors alter HRV in
each of the frequency bands. Assessment of long-term HRV
from 24-hour AECG recordings is influenced by circadian
rhythms and patient activity (139). Thus, because of the
changing autonomic control or modulation of the heart rate
throughout the day, the high- and low-frequency power
components are not stationary, and their link to specific
physiology is therefore less well defined. Analysis of these
bands from short-term recordings during controlled condi-
tions avoids these potentially confounding problems. Time-
and frequency-domain analyses are simply different methods
to examine the same data set. As such, it is not surprising that
a high degree of correlation exists among parameters (140).
There are data to support the reproducibility of these mea-
sures (112). More recently, nonlinear methods have also been
used to examine HRV. These studies are much less well
developed than studies of time- and frequency-domain anal-
ysis. Of the nonlinear techniques that are available, the largest
amount of clinical data is available for the power-law
relationship. To derive the power-law relationship, the
frequency-domain data are plotted [log(power) versus log-
(frequency)], and the inverse slope of this plot helps to define
the complexity of heart rate fluctuations. The complexity of
variability analyzed by nonlinear methods can also be ex-
pressed with fractal scaling or fractal dimension.
The ability of HRV to predict arrhythmic, cardiac, or total
mortality has been studied in a variety of different popula-
tions. In 1987, Kleiger et al (141) reported a relative risk of
5 for all-cause mortality in patients with low time-domain
measures of HRV. Since then, a number of studies have
reported an increased mortality in patients with low time- and
frequency-domain measures of HRV. The ability of
frequency-domain measures to predict mortality appears ap-
proximately equivalent to that of time-domain measures. In
most studies, patients with angina or heart failure and those
who had experienced an MI had a higher mortality if HRV
was low. In general, the relative risk is in the range of 2 to 3,
but lower numbers have been obtained in large population
studies, such as the Framingham study. In different studies,
different time and frequency measures have shown the
highest predictive value for all-cause mortality or sudden
death. Overall, HRV was a better predictor of total mortality
than of SCD mortality (117,119,140,142,143). Of nonlinear
methods, the power-law relationship has been studied the
most extensively. Huikuri et al (144) examined a “random
sample” of 347 subjects who were 65 years old. In that
study, the nonlinear power-law relationship was the best
predictor of all-cause mortality (relative risk7.9, P0.001);
however, in a multivariate analysis, the relative risk de-
creased to 1.74. Time-domain measures did not perform as
well in their analysis. Huikuri et al (145) also examined
1186 Goldberger et al. JACC Vol. 52, No. 14, 2008
Risk Stratification for Sudden Death September 30, 2008:1179–99
short-term fractal scaling () in a different patient population
and found it had a better predictive value than time-domain
measures; however, more large-scale population studies will
be required before there are adequate data to determine
whether this methodology holds promise for risk
stratification.
In most population studies using multivariate analysis,
HRV provides significant, independent prognostic informa-
tion. The Autonomic Tone and Reflexes After MI (ATRAMI)
study (146) showed that after MI, patients with low HRV had
a relative mortality risk of 3.2, with accounting for LVEF and
ventricular ectopy. Two recent intervention trials used HRV
to risk-stratify patients. In DINAMIT (15), 675 post-MI
patients who had decreased LVEF and low HRV (or elevated
heart rate) were randomized to receive or not receive an ICD.
There was no significant difference in survival between the
groups. The ICD reduced arrhythmic mortality, but nonar-
rhythmic mortality increased in the patients who received an
ICD. It was believed that low HRV in this patient population
was an indicator of more advanced hemodynamic disease,
and patients in the ICD group who received appropriate
shocks ultimately died of congestive heart failure. A second
trial used HRV analysis to divide patients into low- and
high-risk groups. Camm et al (147) studied 3717 post-MI
patients with left ventricular dysfunction and characterized
them into low- and high-risk groups on the basis of the
triangular index of HRV. Although the trial was designed to
examine the effects of an antiarrhythmic drug (azimilide) on
survival, data on the prognostic importance of HRV were also
reported. By multivariate analysis, low HRV increased risk of
all-cause mortality with a hazard ratio of 1.46 (95% CI 1.1 to
1.94); however, low HRV did not predict arrhythmic mortal-
ity. In the Marburg Cardiomyopathy Study (24), of the 263
patients with nonischemic dilated cardiomyopathy who were
in sinus rhythm, low HRV was not a multivariate predictor of
transplant-free survival or of arrhythmic events.
Conclusions
Abundant data show that depressed HRV is a predictor of
total mortality. Despite the theoretical pathophysiological
link among abnormal HRV, autonomic tone, and arrhythmo-
genesis, the present data show that HRV may be a better
marker of nonarrhythmic mortality. Further studies are
needed to establish whether HRV has a role in risk stratifi-
cation for SCD.
Heart Rate Turbulence
Heart rate turbulence describes the short-term fluctuation in
sinus cycle length that follows a VPB (148). Although the
mechanism of heart rate turbulence is not known with
certainty, it has been postulated that it measures vagal
responsiveness in a fashion similar to baroreflex sensitivity
(BRS). After a premature beat and a compensatory pause,
there is a typical increase in blood pressure due to the
prolonged filling in the cycle of the compensatory pause.
Reflex parasympathetic activation ensues and slows the heart
rate. This parasympathetic reactivation can be defined by the
time of onset of the return of the heart rate to normal and the
slope (turbulence slope) of that return. Heart rate turbulence
requires the response to a number of premature beats (15 to
20) to be averaged. As with other techniques that purport to
measure the effects of autonomic tone on the sinus node, a
higher slope, which indicates more parasympathetic respon-
siveness, should correlate with improved prognosis. Heart
rate turbulence has been examined primarily in post-MI
patients (148 –150). The relative risk imparted by low heart
rate turbulence in patients who have had an MI appears
impressive. For example, in an ATRAMI substudy (151),
there was a relative risk of 4 in multivariate analysis. A
composite autonomic index, which included BRS and time-
domain measures of HRV, increased the relative risk to 8. A
smaller number of studies of patients with nonischemic
dilated cardiomyopathy, chronic congestive heart failure, or
hypertrophic cardiomyopathy (HCM) and patients undergo-
ing revascularization have also suggested a predictive value
of heart rate turbulence (24,149,151–154). In the Marburg
Cardiomyopathy Study of 242 patients with nonischemic
dilated cardiomyopathy (155), heart rate turbulence onset was
a multivariate predictor of transplant-free survival (relative
risk 2.95, 95% CI 1.11 to 7.48) but not of arrhythmic events.
Heart rate turbulence is potentially attractive as a risk
stratification tool because it can be performed with a rela-
tively small number of premature beats from 24-hour AECG
and does not require blood pressure monitoring or interven-
tion, as BRS does. Further data regarding its reproducibility
are needed. Although some studies suggest it has significant
predictive value after MI, only a few studies have been
completed. Follow-up in some studies was not long term, and
intervention trials based on heart rate turbulence have not
been performed.
Conclusions
Emerging data show that abnormal heart rate turbulence is
associated with increased mortality. Further studies are
needed to establish whether there is clinical utility of this
parameter for risk stratification.
Exercise Test/Functional Status
Exercise Capacity and NYHA Class
Left ventricular dysfunction is well established as a risk
factor for sudden death; however, the clinical syndrome of
congestive heart failure itself can also contribute to arrhyth-
mogenesis in patients with ventricular dysfunction and can
increase mortality in patients with either an ischemic or
nonischemic dilated cardiomyopathy, independent of LVEF.
Heart failure is associated with many factors that predispose
to ventricular arrhythmias, including increased circulating
catecholamines, electrolyte imbalances caused by diuretic
use, prolonged repolarization, stretch-induced afterdepolar-
izations, and Purkinje system conduction delay. Manifesta-
tions of neurohormonal activation, such as hyponatremia and
increased plasma norepinephrine, renin, and natriuretic pep-
tide levels, have been found to be predictive of mortality
(156). Some medical therapies for congestive heart failure
have been shown to reduce both progressive heart failure and
SCD due to cardiovascular causes (2,157).
ICD trials have found that heart failure symptoms are
associated with defibrillator therapies. A recent study, the
Triggers Of Ventricular Arrhythmias (TOVA), identified
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NYHA functional class III as the strongest independent
predictor of appropriate ICD therapy (158). SCD-HeFT found
a mortality benefit from ICD therapy for primary prevention
among patients with congestive heart failure and either an
ischemic or nonischemic dilated cardiomyopathy. Subgroup
analysis showed that patients with class III heart failure did
not appear to benefit compared with patients with class II
heart failure (22). On the other hand, DEFINITE, which
enrolled only patients with a nonischemic cardiomyopathy,
found a greater benefit of ICD therapy among patients with
class III heart failure than among patients with class II heart
failure (25). In MADIT-II, which enrolled only post-MI
patients, there were no significant differences in the benefi-
cial effect of ICD therapy on survival in subgroup analyses
stratified according to NYHA class (21).
The primary limitation of the use of heart failure severity to
risk-stratify patients with systolic dysfunction for SCD is that
although mortality increases with the severity of heart failure,
the proportion of deaths due to SCD decreases as deaths due
to progressive pump failure increase (156). The Metoprolol
CR/XL Randomized Intervention Trial in Chronic Heart
Failure (MERIT-HF) showed that the overall mortality rate
for patients with NYHA class II symptoms was 5% and that
85% of those deaths were sudden. In contrast, the overall
mortality rate for patients with class IV symptoms was 21%,
with only 33% of those being SCDs. Therefore, even if ICD
therapy eliminated SCD in patients with advanced heart failure,
it is not clear what the net overall impact would be on mortality.
The use of heart failure classification to identify patients
with systolic dysfunction who are at risk for SCD is also
limited by its subjectivity. One study found that NYHA
estimates made by 2 physicians had a reproducibility of only
56% and that only 51% of the estimates agreed with treadmill
exercise performance (159). Another important limitation of
heart failure functional status is that patients frequently
transition from 1 class to another over time. Objective
measures of functional capacity, such as peak oxygen con-
sumption with exercise and the 6-minute hall walk test, have
been shown to be reliable and reproducible (160,161). Mea-
surement of peak oxygen uptake with exercise appears to be
superior to clinical variables, hemodynamics, and exercise
time in predicting mortality in patients with severe chronic
heart failure (162). Although measurements during exercise
are more objective than NYHA classification, these tests
appear to be no more specific for mode of death than
functional classification (162).
Conclusions
Although the syndrome of congestive heart failure may
predispose to ventricular arrhythmias and SCD in patients
with systolic dysfunction, its value as a risk stratification tool
is untested. Furthermore, although overall mortality increases
as the severity of heart failure increases, the proportion of
deaths due to sudden cardiac arrest from a treatable ventric-
ular tachyarrhythmia decreases as more patients die of pro-
gressive pump failure.
Heart Rate Recovery and Recovery
Ventricular Ectopy
Immediately after graded exercise, heart rate normally falls in
a biphasic manner, with an initial rapid decline occurring
during the first 30 seconds to 1 minute of recovery (163).
Imai and colleagues (163) demonstrated that this initial steep
descent is marked in athletes and attenuated in patients with
heart failure and that it can be eliminated by administration of
atropine. Thus, parasympathetic reactivation likely plays a
major role in regulating heart rate recovery. Because impaired
parasympathetic tone correlates with increased risk of death,
it was hypothesized that an attenuated heart rate recovery
would similarly predict an increased risk of death. In a cohort
study of 2428 patients who were referred for exercise
myocardial perfusion imaging and who were candidates for
first-time coronary angiography, a 1-minute heart rate recov-
ery 12 beats per minute was associated with a markedly
increased risk of all-cause death (positive predictive value
19%, negative predictive value 95%, confounder-adjusted
hazard ratio 2.0, 95% CI 1.5 to 2.7) (164).
Subsequent investigations have confirmed the link between
decreased heart rate recovery and all-cause death in a variety
of groups (165). Specifically, heart rate recovery has been
shown to be predictive of mortality even after accounting for
the Duke treadmill exercise score (166), left ventricular
systolic function (167), the type of recovery protocol used
(164,167,168), and angiographic severity of coronary disease
(169). Heart rate recovery predicts mortality along with
exercise capacity in men with diabetes mellitus (170). Among
patients with imaging evidence of ischemia, a low heart rate
recovery identifies patients for whom the survival benefit of
revascularization is attenuated (164); that is, patients with
ischemia are most likely to realize improved survival if heart
rate recovery is normal. Investigators from the Paris Civil
Servants study reported a link specifically between heart rate
recovery and SCD, but these subjects were all free of
cardiovascular disease at the time of exercise testing (168).
Despite the strong data linking heart rate recovery to
mortality, its routine use for clinical risk stratification has
been brought into question (171). The ideal recovery protocol
and abnormal cutoff value are unclear; some advocate an
upright cool-down period with a cutoff value of 12 beats
per minute into recovery (164,166), whereas others support a
sit-down recovery with a cutoff value of 22 beats per
minute at 2 minutes into recovery (165). When a supine
recovery is mandated, as in stress echocardiography, a cutoff
value of 18 beats per minute has been described (167). In
addition, the reproducibility of an abnormal result may not be
sufficient to apply the test for individual (versus population)
risk stratification (172). There are no substantive data in
patients with dilated cardiomyopathy.
A phenomenon related to heart rate recovery is ventricular
ectopy during recovery, which has also been hypothesized to
reflect parasympathetic activity. Occurrence of frequent or
severe ventricular ectopy during the first 5 minutes of
recovery after exercise has been linked to risk of death in
patients without and with heart failure and/or coronary artery
disease (173,174).
Conclusion
Although heart rate recovery and ventricular ectopy during
recovery are new and interesting markers of mortality, their
value as risk stratification tools for SCD is untested.
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T-Wave Alternans
In 1994, Rosenbaum et al (175) first related T-wave alternans
to high-risk findings on electrophysiological testing and to an
increased risk of serious arrhythmic events. T-wave alternans
is a reflection of repolarization alternans at the level of the
single cell and most likely arises when heart rate exceeds the
capacity of cardiac cells to cycle intracellular calcium (176).
Therefore, T-wave alternans is a rate-dependent phenomenon
and tends to occur at relatively lower heart rates in patients
susceptible to life-threatening ventricular arrhythmias. Inter-
estingly, by amplifying electrical heterogeneities between
neighboring cardiac cells, T-wave alternans has been directly
linked to a mechanism of arrhythmogenesis (177). Detection
of T-wave alternans requires graded exercise to elevate heart
rate, as well as special electrodes and processing to record the
microvolt-level T-wave alternans with high fidelity. Because
of the need to achieve a target heart rate with regular R-R
intervals, a significant percentage of tests are indeterminate
owing to either failure to reach target heart rate, atrial
fibrillation, or frequent ectopic activity. T-wave alternans is
moderately reproducible, with concordance on repeated tests
of 65% to 75% (178,179) and 80% to 90% when only patients
with determinate results are considered (178,179).
A number of observational cohort studies have been
published that suggest that microvolt T-wave alternans may
work at least as well as electrophysiological testing for
prediction of SCD or major arrhythmic events. Recent cohort
studies that involved at least 100 patients found that T-wave
alternans was associated with substantially increased risk and
predicted events as well as or better than other markers,
including LVEF, electrophysiological testing, SAECG, BRS,
and HRV (97,105,180 –182). Furthermore, T-wave alternans
predicted risk in patients with coronary artery disease
(181,183) and in patients with dilated cardiomyopathy (105).
In all of these studies, patients not manifesting T-wave
alternans were at low risk for SCD.
Two important methodological considerations are the type
of stress used to induce T-wave alternans and the threshold
for labeling a test abnormal. Although pacing-induced
T-wave alternans has been linked to ventricular arrhythmia
risk (182), one head-to-head comparison study found that
exercise-induced T-wave alternans was a better predictor
(183). The typical definition for an abnormal T-wave alter-
nans test is the occurrence of1.9 V of alternans starting at
a heart rate of 110 beats per minute. Tanno and colleagues
(182), in a study of pacing-induced T-wave alternans, found
that increasing the heart rate cutoff can increase the negative
predictive value to 100% but at the cost of a lower positive
predictive value. Of note, a significant percentage of tests are
indeterminate; many studies have classified these patients as
nonnegative and have noted a similar prognosis as that for
patients with a positive result. This may relate to the under-
lying factors responsible for the indeterminate test, ie, inabil-
ity to achieve the necessary heart rate.
Despite the consistency of the reports linking T-wave
alternans to risk, published studies are limited by the some-
times highly select patient samples, relatively low number of
end points, use of composite end points (184), and lack of
randomization. One recent cohort study of 177 patients with
coronary artery disease and LVEF 30% suggested that
T-wave alternans may be better than QRS duration for
identifying patients likely to benefit from ICDs (185). The
hazard ratios for 2-year mortality were 4.8 for abnormal
T-wave alternans and 1.5 for prolonged QRS duration. A
multicenter study (186) of 549 patients (49% with coronary
artery disease) with LVEF 40% who underwent T-wave
alternans testing reported that the 2-year event (death or
nonfatal sustained ventricular tachyarrhythmia) rate was
12.3% in the 162 patients with a positive test, 17.5% in the
198 patients with an indeterminate test, and 2.5% in the 189
patients with a negative test (hazard ratio 6.5 for an abnormal
test). Event rates were significantly greater in patients with
both ischemic and nonischemic heart disease who had abnor-
mal versus normal T-wave alternans (16.8% and 13.3%,
respectively, for an abnormal result versus 4.8% and 0%,
respectively, for a normal result). Similarly, an observational
study (187) of 768 patients with ischemic cardiomyopathy
(LVEF 35%) found that a positive or indeterminate T-wave
alternans test was associated with increased mortality risk
(stratified hazard ratio 2.24, 95% CI 1.34 to 3.75) and
increased risk of arrhythmic mortality (stratified hazard ratio
2.29, 95% CI 1.00 to 5.24). In contrast, in the Marburg
Cardiomyopathy Study (24), T-wave alternans was neither a
univariate nor a multivariate predictor of either transplant-
free survival or arrhythmic events. A meta-analysis of 19
studies including 2608 patients (188) demonstrated that
T-wave alternans was a strong univariate predictor of arrhyth-
mic events in patients with ischemic heart failure (relative
risk 2.42, 95% CI 1.30 to 4.50) and nonischemic heart failure
(relative risk 3.67, 95% CI 1.50 to 8.96).
Although data support the use of T-wave alternans as a risk
factor for SCD, the precise role of the use of this technology
is unclear. The value of T-wave alternans may be enhanced
when combined with other major risk predictors (181). Two
large trials presented their findings at the 2006 Scientific
Sessions of the American Heart Association regarding the use
of T-wave alternans. The ABCD trial, which enrolled 566
patients with coronary artery disease and LVEF40%, found
that a positive T-wave alternans test was as predictive of
arrhythmic events as a positive electrophysiology study.
Importantly, the event rate for patients in whom both tests
were negative was low. In contrast, a 490-patient substudy of
SCD-HeFT found no significant difference in arrhythmic
events between those who had a positive versus a negative
T-wave alternans test. Of note, 41% of the population had an
indeterminate result.
Conclusions
A moderate amount of data suggest that T-wave alternans
may be useful for risk stratification for SCD. Further infor-
mation will be required to determine how to implement this
test in clinical practice.
Baroreceptor Sensitivity
BRS refers to the adaptation of cardiac periods (R-R inter-
vals) to changes in blood pressure. The baroreflex mechanism
has been established as a central part of the regulation of the
cardiovascular system, particularly in the control of parasym-
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pathetic and sympathetic outflow to the heart and the periph-
eral vessels (189).
There are different methods of evaluating BRS, but the one
that is most applicable to routine clinical use is probably the
phenylephrine method (189). In essence, BRS is assessed by
this method during a brief period of controlled blood pressure
change. Most often, such a provocation is caused by the
injection of an intravenous bolus of phenylephrine (an
-agonist that causes reflex parasympathetic enhancement).
Precise, simultaneous recordings of the ECG-derived R-R
intervals and systolic blood pressure values are necessary to
calculate BRS. Specifically, BRS is expressed as the slope of
the regression line showing the dependency of R-R intervals
on blood pressure values. In healthy individuals, the intrave-
nous administration of 25 to 100 g of phenylephrine results
in a20-mm Hg increase in systolic blood pressure, and R-R
intervals are prolonged by 10 ms for each 1-mm Hg of
pressure increase. Under optimal experimental conditions,
BRS is only moderately reproducible, with a coefficient of
variation of 38% on repeated tests (189).
Extensive experimental work convincingly demonstrated a
close link between reduced BRS and increased risk for
serious ventricular tachyarrhythmias (190). La Rovere et al
(191) prospectively determined BRS in 78 post-MI patients
who were followed up for 2 years, during which time 7
cardiovascular deaths occurred, including 4 sudden deaths.
BRS was significantly lower in the 7 deceased patients than
in the survivors. These results were subsequently confirmed
by other studies (192,193). An important step toward estab-
lishing BRS determination for risk stratification after MI was
achieved by the multicenter, prospective ATRAMI study
(146). In contrast to most previous studies, ATRAMI was a
prospective study evaluating the accuracy of BRS and HRV
in predicting cardiac mortality. The trial used prospectively
defined cutoff values for both autonomic markers. In 1284
postinfarction survivors, HRV and BRS were assessed at the
time of hospital discharge. During 21 months of follow-up,
there were 44 cardiac deaths and 5 nonfatal cardiac arrests.
Depressed HRV (standard deviation of normal 70 ms) or
BRS (3.0 ms/mm Hg) carried a significant multivariate risk
of cardiac mortality (3.2 [95% CI 1.4 to 7.4] and 2.8 [1.2 to
6.2], respectively). Risk increased further when both param-
eters were depressed. The association of low BRS or SDNN
with a reduced LVEF (35%) carried a relative risk of 8.7
(4.3 to 17.6) or 6.7 (3.1 to 14.6), respectively, compared with
patients with better preserved LVEF and less compromised
HRV or BRS. The main conclusion from this important trial
is that early after acute MI, the analysis of parasympathetic
reflexes yields significant prognostic value independent of
LVEF or other noninvasive risk stratifiers. Analysis of BRS
adds to the prognostic value of HRV, which signifies that
measures of autonomic tone and parasympathetic reflex
activity are not redundant but rather complementary (146).
Subsequent analyses showed that when examined in con-
junction with depressed LVEF, BRS contributed in a novel
way to risk stratification. Specifically, within the group of
patients with LVEF 35%, those with preserved BRS had a
significantly better 2-year survival than those with depressed
BRS. This was even more evident for major arrhythmic
events (3% versus 16%). The latter analysis must certainly be
repeated in larger patient populations. In the Marburg Car-
diomyopathy Study (24), of the 263 patients with nonische-
mic dilated cardiomyopathy who were in sinus rhythm, BRS
was not a multivariate predictor of arrhythmic events but
exhibited a trend toward predicting transplant-free survival
(relative risk 1.42, 95% CI 0.95 to 2.13).
Conclusions
A moderate amount of data suggest that BRS may be useful
for risk stratification for SCD in patients with coronary artery
disease. Further studies are needed to establish the clinical
utility, if any, of this parameter for risk stratification.
Other Testing
In addition to the noninvasive testing described in detail
above, there are several other tests that may be useful for risk
stratification. Evaluation of myocardial ischemia is clearly
important, because this may serve as an important trigger for
life-threatening ventricular arrhythmias, either in patients
with preexisting substrate or, less commonly, as a primary
cause. Electrophysiological testing has demonstrated utility in
identifying the substrate for sustained VT and could become
an important part of a risk stratification strategy. Finally,
newer techniques, such as characterization of infarct size or
morphology by contrast-enhanced magnetic resonance imag-
ing, could provide information on susceptibility to ventricular
tachyarrhythmias in patients with coronary artery disease
(194) and nonischemic dilated cardiomyopathy (195).
Hypertrophic Cardiomyopathy
Because HCM is the most common cause of SCD in the
young, including competitive athletes (196), the unique risk
stratification issues related to HCM are reviewed. HCM is a
genetic heart disease with heterogeneous clinical expression.
Although only a minority of the overall HCM population are
at high risk for sudden death, strategies for risk stratification
and isolation of that important subset have constituted a
major investigative focus (197). It has also been appreciated
(197) that the literature may have previously overestimated
the risks associated with HCM, because many of the pub-
lished data had been derived from tertiary referral centers
with disproportionate numbers of high-risk patients.
In contrast to the ischemic and nonischemic cardiomyop-
athies under consideration in the present statement, the vast
majority of patients with HCM at risk for SCD are young,
asymptomatic (or mildly symptomatic) adolescents or adults
35 years old. These patients may not have reliable warning
signs, and thus, SCD can be the initial disease presentation.
However, SCD risk also extends through midlife and beyond;
therefore, achieving any particular age does not itself confer
immunity to sudden death.
Many of the tests or parameters described in this statement
to assess risk for SCD in ischemic and nonischemic cardio-
myopathies are generally not applicable to patients with
HCM. These include 12-lead ECG patterns, which are usually
abnormal and particularly heterogeneous in HCM, with little
predictive value regarding outcome. Because HCM is char-
acterized by hyperdynamic or normal left ventricular func-
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tion, LVEF has little or no prognostic power, except in the
small minority of patients in the end-stage phase with systolic
dysfunction due to diffuse LV scarring. Heart rate recovery,
HRV, SAECG, and T-wave alternans have not been well
studied as markers of SCD risk in this disease.
Because of the relatively low prevalence of HCM in
general cardiological practice, its diverse presentation and
mechanisms of death, and skewed patient referral patterns,
the level of evidence governing risk stratification strategies
has most often been derived from nonrandomized and retro-
spective investigations. Furthermore, the long risk period for
this relatively young patient population and the low SCD
event rate represent obstacles to developing and testing risk
stratification strategies. Large-scale controlled and random-
ized study designs, such as those that have provided impor-
tant answers regarding the management of coronary artery
disease and congestive heart failure, have generally not been
available in HCM patients owing to these demographic
factors. Additionally, most of the clinical markers of SCD
risk in HCM are limited by relatively low positive predictive
value (20%), largely due to low event rates. However, high
negative predictive values attributable to these markers (90%)
suggest that the absence of risk factors may be used to develop
a profile of those patients with low likelihood of sudden death.
The highest risk for SCD (197–200) has been associated
with 1) prior cardiac arrest or spontaneously occurring
sustained VT; 2) family history of a premature HCM-related
death, particularly if SCD occurred in a close relative, or
when multiple; 3) unexplained syncope, particularly in young
patients; 4) NSVT (usually asymptomatic short bursts of 3 to
6 beats at 120 bpm) on long-term AECG recordings,
particularly if prolonged or multiple/repetitive on serial stud-
ies; 5) attenuated or hypotensive blood pressure response
during upright exercise, indicative of hemodynamic instabil-
ity; and 6) extreme left ventricular hypertrophy with maxi-
mum wall thickness 30 mm on 2-dimensional echocardi-
ography, particularly in adolescents and young adults.
Available data suggest that left ventricular outflow obstruc-
tion (gradient30 mm Hg at rest) assessed by continuous-wave
Doppler echocardiography can only be regarded as a minor risk
factor for SCD in HCM (positive predictive value of only
7%) (201). Myocardial ischemia (associated with impaired
coronary vasodilator capacity), in the absence of coronary
artery disease, is probably an important pathophysiological
mechanism in HCM, as a consequence of abnormal micro-
vasculature (ie, intramural “small-vessel disease”). However,
ischemia (or its consequences) as a prognostic marker in
HCM has proved to be difficult to assess with standard
exercise testing, thallium imaging, echocardiography, or
magnetic resonance imaging. Positron electron tomography
has shown a significant relationship between myocardial
ischemia and the progression of heart failure in HCM, but not
specifically with sudden death. It has also been proposed, on
the basis of genotype-phenotype correlations in a relatively
small number of families, that the genetic defects responsible
for HCM could represent the primary determinant of SCD
risk, with specific mutations conveying either favorable or
adverse prognosis. However, the clinical utility of genetic
testing for predicting prognosis and developing individual
patient management strategies is uncertain.
Although the available data on risk stratification for SCD
are substantial, it is important to underscore that precise
criteria for identification of high-risk patients by clinical risk
markers are not complete. Although it has been possible to
identify many such patients only by history taking or nonin-
vasive testing, a minority of HCM patients who die suddenly
are without any of the currently acknowledged risk factors.
Although there likely is a need for serial testing, there are no
data to establish with what frequency 2-dimensional echocardi-
ography, ECG, AECG, and exercise testing should be repeated.
Conclusions
Observational data regarding risk stratification for SCD in
HCM at present support testing with ECG, AECG, treadmill
(or bicycle) exercise, and 2-dimensional echocardiography, in
addition to obtaining a personal and family history. There are
no randomized trials that use these parameters.
Patient-Based Approach to
Risk Stratification
When an individual patient is being evaluated to assess his or
her risk for SCD, there are several important issues that
should be addressed. First and foremost, the specific goal for
risk stratification for the individual patient should be identi-
fied. The choice of tests may vary if the goal is to determine
the appropriateness of implanting an ICD versus titrating the
aggressiveness of medical therapy versus providing the pa-
tient with information regarding his or her prognosis. At this
time, there is no consensus regarding the level of risk that
justifies an intervention, based on either the level of benefit or
cost associated with the intervention. This is further com-
pounded by the fact that the risk-benefit ratio of an interven-
tion in an individual patient could differ from that observed in
large-scale trials. In addition, individual and societal toler-
ance for risk may differ. These issues are not subject to
evaluation in clinical trials, and therefore, only sound clinical
judgment can be used by the practitioner to address them.
Another important issue is assessing the timing of evalua-
tion. Early attempts at risk stratification focused on evaluat-
ing patients in the early postinfarction period (8). Many
studies have demonstrated time-dependent changes in many
of the risk stratification techniques discussed in this state-
ment, including LVEF, ventricular ectopy, the SAECG, and
HRV. Although there is a continued and perhaps even an
enhanced risk for SCD in patients remote from their MI
(202), there does remain a heightened mortality risk in the
first several months postinfarction for which the cause is
unclear. Most ICD primary prevention trials have specifically
excluded these patients and only enrolled patients remote
from their MI. In contrast, the DINAMIT study (15), which
enrolled patients within 40 days of an MI who had low LVEF
(35%) and low HRV, did not show a survival benefit for
those treated with an ICD. Similarly, the CABG-Patch trial
(17) enrolled patients with coronary artery disease who had
low LVEF and positive SAECGs and also found no survival
benefit for those treated with an ICD. Although it is tempting
to identify the SAECG or the HRV as the risk stratification
technique that failed to identify the appropriate high-risk
patients who would benefit from an ICD, it must be empha-
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sized that these patients all had low LVEF. Because
MADIT-II and SCD-HeFT, which included patients with
similarly low LVEF, demonstrated a survival benefit with an
ICD, it appears likely that the clinical settings (early postin-
farction period or post-CABG surgery) may also affect the
etiology of SCD and therefore the utility of the risk stratifi-
cation techniques. Furthermore, it was recently shown that
eplerenone reduced the risk of SCD by 37% at 30 days in a
randomized trial of patients with acute MI, left ventricular
systolic dysfunction, and heart failure (203), which suggests
that alternative therapies may be required during this time
period to reduce the risk of SCD. The Cardiac Arrhythmias
and RIsk Stratification after Myocardial infArction (CAR-
ISMA) study (204) is a multicenter study enrolling patients
with an LVEF 40% after acute MI in whom a loop recorder
is implanted to evaluate the incidence of tachyarrhythmia and
bradyarrhythmia episodes. This study will specifically eval-
uate the value of 24-hour AECG, SAECG, QT dispersion,
T-wave alternans, and electrophysiological testing as predic-
tors of life-threatening arrhythmias in the early postinfarction
period. Risk stratification approaches and interventions will
need to be related to the timing of evaluation in the patient’s
disease process. Further efforts to define the appropriate evalu-
ations and treatments relative to this timing are necessary.
There are no data that identify the optimum risk stratifica-
tion strategy or combination of tests to be performed. The
optimal strategy should identify the vast majority of those
who will experience sudden arrhythmic death and a minimal
number of those who will not. No existing strategies attain
this goal. There are a large number of clinical studies that
have combined available techniques, with demonstrable im-
provement in sensitivity and specificity. Randomized ICD-
intervention clinical trials have generally combined depressed
LVEF with at most 1 other risk stratifier. The inadequacy of
these approaches is underscored by the fact that most victims
of SCD do not have low LVEF. Thus, much research is
required to determine which of the myriad available tests
should be performed, whether they should be performed
sequentially or simultaneously, and whether a patient’s risk
should be assessed at some frequency in the absence of a
change in clinical status. It is clear that continued progress in
noninvasive risk stratification will benefit by the determina-
tion of whether the suboptimal success achieved with each
approach can be improved with use of tests in combination
and/or refinements in methodology to more completely detect
the pathophysiological determinants of VT/VF.
Tremendous efforts have been made in developing and
studying risk stratification techniques; however, at present,
there are no data integrating the use of these techniques into
a coherent strategy for intervention. Currently, the primary
technique for stratifying risk to determine who is an appro-
priate candidate for an ICD for primary prevention of SCD is
the LVEF. It is reasonable to place patients with LVEF
30% to 35% in the highest-risk group that can be identified
presently. This applies to patients with coronary artery disease
and dilated cardiomyopathy. Future studies will assess whether
further risk stratification within this population can be achieved.
This will require the development of a risk stratification test or
strategy with high negative predictive value. In patients with
coronary artery disease and LVEF 35%, further testing with
other risk stratification techniques (14) may be used, but data on
how to apply the results of these tests are lacking. If clinical
evaluation is consistent with an increased risk, further electro-
physiological testing may be indicated.
The field of risk stratification requires substantial further
development. Although the lack of a dominant strategy using
these techniques is certainly due in part to the absence of
clinical trial data, it is also important to consider that there
may be limitations to the current techniques. Most of these
techniques focus on the evaluation of electrical, autonomic,
or anatomic substrates of the patient at rest, when the risk of
SCD is low. Some of the techniques involve evaluations
during exercise and the postexercise recovery period, times of
relatively increased risk for SCD and ventricular arrhythmias.
Clearly, there are other factors that may be implicated in the
pathophysiology of SCD. Recent consensus documents have
outlined the concepts of vulnerable plaque, vulnerable blood
(prone to thrombosis), and vulnerable myocardium (205,206).
Newer approaches that encompass a more general evaluation
of “vulnerability” to sudden death, including genetic profil-
ing, serum markers, and new imaging approaches, are neces-
sary. Finally, if risk stratification is to be applied to a
population with an overall low risk of SCD to identify a
subgroup with more significant risk, it is likely that multiple
tests will need to be incorporated into a risk stratification
strategy; a single test, even with good sensitivity and speci-
ficity, when applied to a population with a low incidence of
SCD will have a poor positive predictive value. Although it is
possible that multiple positive test results could be used to
identify particularly high-risk individuals, it is also possible
that such a strategy would limit the proportion of the “at risk”
population that can be identified.
Summary
Given the availability of therapies to prevent SCD due to
otherwise fatal ventricular tachyarrhythmias, it is important to
differentiate noninvasive risk stratification techniques that
enhance the ability to identify SCD from total mortality. The
relative ability for each of the described techniques varies,
and the optimal way to combine and use these techniques in
clinical practice remains unclear. Low LVEF, which is the
most widely used test on which ICD intervention is recom-
mended, does not have a particularly high discriminatory
ability to identify SCD rather than non-SCD mortality.
Although data exist supporting the concept that noninvasive
risk stratification techniques may be useful to identify pa-
tients with low LVEF who are at low risk for SCD, this
requires further testing. There are also data to support the
concept that noninvasive risk stratification techniques may be
useful to identify patients who do not have low LVEF who
nevertheless are at substantial risk for SCD. Because most
SCD occurs in this latter group, substantial effort is justified
in evaluating, testing, and ultimately implementing risk strat-
ification strategies in this group.
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